Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns

About Contact Login Home Pharma News Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns Pharmaceutical 21 July 2026 Danish pharma major Novo Nordisk NOV:

About Contact Login Home

Pharma News

Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns Pharmaceutical 21 July 2026 Danish pharma major Novo Nordisk NOV: N today revealed it has filed a lawsuit against arch rival in the weight management sector, Eli Lilly NYSE: LLY , in the US District Court for the District of New Jersey for multiple violations of federal and state false advertising and unfair competition laws, including under the Lanham Act.

The lawsuit challenges Lilly's nationwide direct-to-consumer advertising for Zepbound tirzepatide and Mounjaro tirzepatide as false and materially misleading to the millions of Americans living with obesity and type 2 diabetes because it omits relevant information about the most effective injectable doses of Wegovy semaglutide and Ozempic semaglutide available.

This action follows Lilly's refusal to pull down or meaningfully correct certain ads, despite a formal cease-and-desist request from Novo Nordisk.

This article is accessible to registered users, to continue reading please register for free.

A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week.

If you are already a registered user please login.

If your trial has come to an end, you can subscribe here.

Join industry leaders for a daily roundup of biotech & pharma news BiotechnologyEU expands Crysvita approval to infants with rare phosphate disorder 21 July 2026 PharmaceuticalAstraZeneca launches Breztri in USA asthma after FDA approval 21 July 2026 PharmaceuticalMHRA approves Chiesi's carbon minimal inhaler - a world first 21 July 2026 BiotechnologyAllogenetics appoints Jeroen Rovers as CMO 21 July 2026 PharmaceuticalNovartis delivers 3% sales growth in 2nd-qtr 2026 21 July 2026 BiotechnologyKolon TissueGene’s TG-C misses endpoints in pivotal knee osteoarthritis trial 21 July 2026 PharmaceuticalTempus AI snaps up genomics partner Personalis for $1.5 billion 21 July 2026 Company Spotlight Jasper Therapeutics A biotechnology company focused on developing novel antibody therapies targeting c-Kit CD117 to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes MDS as well as novel stem cell transplant conditioning regimes.

More Features in Pharmaceutical AstraZeneca launches Breztri in USA asthma after FDA approval 21 July 2026 MHRA approves Chiesi's carbon minimal inhaler - a world first 21 July 2026 Novartis delivers 3% sales growth in 2nd-qtr 2026 21 July 2026 Tempus AI snaps up genomics partner Personalis for $1.5 billion 21 July 2026 The Pharma Letter Twitter

Linkedin | Headless Content Management with Blaze

Peptides referenced: Semaglutide, Tirzepatide, GLP-1.